1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
Publication
, Conference
Petrylak, DP; Azad, AA; Szmulewitz, RZ; Iguchi, T; Shore, ND; Holzbeierlein, J; Alekseev, B; El-Chaar, NN; Rosbrook, B; Ma, J; Zohren, F ...
Published in: Annals of Oncology
September 2022
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2022
Volume
33
Start / End Page
S1183 / S1184
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Petrylak, D. P., Azad, A. A., Szmulewitz, R. Z., Iguchi, T., Shore, N. D., Holzbeierlein, J., … Armstrong, A. J. (2022). 1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES. In Annals of Oncology (Vol. 33, pp. S1183–S1184). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.1884
Petrylak, D. P., A. A. Azad, R. Z. Szmulewitz, T. Iguchi, N. D. Shore, J. Holzbeierlein, B. Alekseev, et al. “1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES.” In Annals of Oncology, 33:S1183–84. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1884.
Petrylak DP, Azad AA, Szmulewitz RZ, Iguchi T, Shore ND, Holzbeierlein J, et al. 1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES. In: Annals of Oncology. Elsevier BV; 2022. p. S1183–4.
Petrylak, D. P., et al. “1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1183–84. Crossref, doi:10.1016/j.annonc.2022.07.1884.
Petrylak DP, Azad AA, Szmulewitz RZ, Iguchi T, Shore ND, Holzbeierlein J, Alekseev B, El-Chaar NN, Rosbrook B, Ma J, Zohren F, Haas GP, Stenzl A, Armstrong AJ. 1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES. Annals of Oncology. Elsevier BV; 2022. p. S1183–S1184.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2022
Volume
33
Start / End Page
S1183 / S1184
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis